Virgili A, Corazza M, Minghetti S, Borghi A
Sezione di Dermatologia e Malattie Infettive, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara.
Sezione di Dermatologia e Malattie Infettive, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara.
Maturitas. 2015 Jan;80(1):113-5. doi: 10.1016/j.maturitas.2014.09.005. Epub 2014 Sep 27.
Vulvar lichen sclerosus (VLS) is a chronic inflammatory disease with a huge impact on a person's quality of life. On the basis of the immunologic changes in VLS, treatment with a high potency topical corticosteroid is recommended. The currently available guidelines identified the ultra-potent corticosteroid clobetasol propionate 0.05% (CP) as the first-line recommended treatment but growing evidence supports the use of the potent corticosteroid mometasone furoate 0.1% (MMF). We reviewed the available studies assessing MMF in the treatment of VLS. Both non comparative and comparative studies were included in this review. Findings from clinical trials indicate that MMF is an effective and safe option in the treatment of VLS both in the active phase and in long-term maintenance treatment. Consistent with the findings from the comparative studies, MMF shows similar efficacy and safety to CP.
外阴硬化性苔藓(VLS)是一种对人的生活质量有巨大影响的慢性炎症性疾病。基于VLS的免疫变化,建议使用高效外用皮质类固醇进行治疗。目前可用的指南将0.05%超强效皮质类固醇丙酸氯倍他索(CP)确定为一线推荐治疗药物,但越来越多的证据支持使用强效皮质类固醇0.1%糠酸莫米松(MMF)。我们回顾了评估MMF治疗VLS的现有研究。本综述纳入了非对照研究和对照研究。临床试验结果表明,MMF在VLS的急性期和长期维持治疗中都是一种有效且安全的选择。与对照研究结果一致,MMF显示出与CP相似的疗效和安全性。